<div id="readability-page-1"><p>Maxim Group analyst Naz Rahman has reiterated their bullish  stance on <span>KZIA</span> stock, giving a Buy rating today.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.  </li><li>Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter </li></ul> <p>Naz Rahman has given his Buy rating due to a combination of factors relating to both the clinical and market backdrop for paxalisib. He sees Celcuity’s statistically significant Phase 3 results with its PI3K/mTOR inhibitor as strengthening confidence in the entire class, and by extension validating Kazia’s approach with an orally administered PI3K/AKT/mTOR agent that has shown encouraging tolerability without the high neutropenia rates seen in some IV regimens.</p> <p>Rahman also notes that Celcuity’s pending PDUFA decision and growing deal activity in the PI3K/mTOR arena suggest rising strategic value for high-quality assets in this pathway. With Kazia expanding its triple-negative breast cancer trial and the broader mechanism being further de-risked, he has reduced his revenue risk assumptions for paxalisib and raised his 12‑month price target to $30, reinforcing his Buy recommendation on the stock.</p> <p>In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.</p></div>

KZIA

CELC

<p>Maxim Group analyst Naz Rahman reiterated a Buy rating on Kazia Therapeutics (KZIA), raising the 12-month price target to $30. The upgrade reflects strengthened confidence in Kazia's PI3K/AKT/mTOR strategy, supported by Celcuity's positive Phase 3 results and de-risked mechanisms. Additionally, H.C. Wainwright maintained a Buy rating with an $18 price target.</p>

Analyst Raises Kazia’s Price Target to $30 and Reiterates Buy on Strengthened Confidence in PI3K/AKT/mTOR Strategy